Flagstar Bank NA vs Heron Therapeutics Inc — how do they compare? Flagstar Bank NA trades at $14.23 (market cap $5.82B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Flagstar Bank NA is far larger — about 91.8× Heron Therapeutics Inc's market cap, and Flagstar Bank NA pays a 0.29% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FLG | HRTX | |
|---|---|---|
Market Cap | $5.82B | $63.41M |
Sector | Financials | Health |
52-Week High | $15.36 | $1.49 |
52-Week Low | $10.72 | $0.32 |
Dividend Yield | 0.29% | — |
Enterprise Value | — | $161.31M |
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $13.95, down 1.48% amid a bearish technical signal, though it remains profitable with a net income margin of 2.3% in 2026. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and continues dividend payments, reflecting confidence in its capital position. The stock trades below book value with a P/B of 0.76, offering a potential margin of safety.
The outlook is mixed: analyst consensus is bullish with a $16.85 price target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of growth initiatives, while downside could stem from further earnings misses or economic headwinds affecting the banking sector.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →